Evaluating the role of serum sclerostin as an indicator of activity and damage in Egyptian patients with rheumatoid arthritis: university hospital experience
- 21 December 2019
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 39 (4) , 1121-1130
Abstract
Objective Sclerostin is an osteocyte-derived glycoprotein which inhibits the canonical Wnt pathway essential for osteoblastic activity decreasing bone formation. Its potential role in rheumatoid arthritis (RA) pathogenesis was highlighted by experimental studies. Here we measured the serum sclerostin in RA patients and evaluated its relationship with disease activity and damage. Methods One hundred RA patients and 80 age and sex-matched healthy controls were enrolled in the study. Bone biomarkers were evaluated for all participants including total calcium, phosphorus, alkaline phosphatase, 25-hydroxy vitamin D, and intact parathyroid hormone, in addition to fibroblast growth factor-23 (FGF23) and serum sclerostin. For RA patients, carotid intima-media thickness, brachial artery flow dilatation, and musculoskeletal ultrasonography using ultrasonography-7 joint score were done, and DAS28-ESR was calculated. Results Median serum sclerostin in our patients was 186.5 ± 22.7 pg/ml which was significantly higher than in controls 60.6 ± 7.1 pg/ml (p < 0.002). Serum sclerostin showed no correlation with disease activity, bone erosions, carotid intima-media thickness, brachial flow dilatation, and the examined bone biomarkers. However, it had a strong correlation with FGF23 (r coefficient 0.988, p < 0.000). Conclusion Although serum sclerostin was elevated in RA patients, it could not be used as a prognostic marker for disease activity, bone erosions or atherosclerosis. Key Points • Serum sclerostin may not reflect changes in the joint microenvironment being not correlated with ultrasonography-detected synovitis or erosions. • Serum sclerostin was elevated in RA patients irrespective to their age or gender. • The positive correlation with FGF23 may provide evidence for sclerostin contribution in bone demineralization in RA patients.Keywords
This publication has 50 references indexed in Scilit:
- Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional studyBMC Nephrology, 2013
- Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritisAnnals of the Rheumatic Diseases, 2013
- Role of FGF23 in vitamin D and phosphate metabolism: Implications in chronic kidney diseaseExperimental Cell Research, 2012
- Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent PathwayPLOS ONE, 2011
- Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progressionAnnals of the Rheumatic Diseases, 2011
- Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanismJournal of Bone and Mineral Research, 2011
- The Wnt signaling pathway and rheumatoid arthritisAutoimmunity Reviews, 2010
- Activity assessments in rheumatoid arthritisCurrent Opinion in Rheumatology, 2008
- Oxidative stress and calcium-phosphorus levels in Rheumatoid arthritisIndian Journal of Clinical Biochemistry, 2006
- Ultrasonography of the metatarsophalangeal joints in rheumatoid arthritis: Comparison with magnetic resonance imaging, conventional radiography, and clinical examinationArthritis & Rheumatism, 2004